Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Consensus Recommendation of “Buy” by Brokerages

Oruka Therapeutics, Inc. (NASDAQ:ORKA) has earned a consensus rating of “Buy” from the nine brokerages that are presently covering the firm, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $39.86.

ORKA has been the topic of a number of research analyst reports. HC Wainwright restated a “buy” rating and issued a $45.00 price target on shares of Oruka Therapeutics in a research note on Friday, February 7th. Wedbush restated an “outperform” rating and issued a $40.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, November 19th. Finally, Wolfe Research initiated coverage on shares of Oruka Therapeutics in a research note on Tuesday, February 4th. They issued an “outperform” rating and a $20.00 price target on the stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ORKA. The Manufacturers Life Insurance Company bought a new position in Oruka Therapeutics in the 3rd quarter valued at approximately $1,037,000. FMR LLC bought a new position in Oruka Therapeutics during the 3rd quarter worth approximately $114,763,000. Great Point Partners LLC bought a new position in Oruka Therapeutics during the 3rd quarter worth approximately $12,614,000. Braidwell LP bought a new position in Oruka Therapeutics during the 3rd quarter worth approximately $12,640,000. Finally, Janus Henderson Group PLC bought a new position in Oruka Therapeutics during the 3rd quarter worth approximately $5,840,000. Institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Trading Down 2.2 %

ORKA opened at $10.76 on Friday. The firm has a 50 day moving average of $15.82. Oruka Therapeutics has a 1-year low of $10.61 and a 1-year high of $53.88. The firm has a market cap of $376.60 million, a P/E ratio of -1.72 and a beta of 0.77.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.